Stock MYMX MYMETICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Mymetics Corporation

Equities

MYMX

US62856A3005

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:47:38 2024-02-16 pm EST 		5-day change 1st Jan Change
0.01 USD -96.16% Intraday chart for Mymetics Corporation -.--% -99.69%
2023 Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI

Business Summary

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Number of employees: 2

Sales per Business

USD in Million2021Weight2022Weight Delta
Grants
99.7 %
1 99.3 % 1 99.7 % +113.44%
Sales Other
0.3 %
- - 0 0.3 % -

Sales per region

USD in Million2021Weight2022Weight Delta
European Union and United States
100.0 %
1 100.0 % 1 100.0 % +112.57%

Managers

Managers TitleAgeSince
Ronald Hugo Gerard Kempers CEO
 Chief Executive Officer 56 09-06-30
Mario Amacker PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Thomas Staehelin BRD
 Director/Board Member 76 07-07-01
Ulrich Burkhard BRD
 Director/Board Member 63 12-03-22
Marcel B. Rüegg BRD
 Director/Board Member - 23-01-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 151,879 73,993 ( 48.72 %) 0 48.72 %

Shareholders

NameEquities%Valuation
IAT Reinsurance Co. Ltd.
0.7197 %
1,093 0.7197 % 11 $
Meeschaert Asset Management SA
0.0461 %
70 0.0461 % 1 $

Company contact information

Mymetics Corp.

Route de la Corniche 4

1066, Epalinges

+41 21 653 4535

http://www.mymetics.com
address Mymetics Corporation(MYMX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MYMETICS CORPORATION Stock Mymetics Corporation
-99.69% 1.52K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.70% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.42% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-15.83% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-12.96% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.07% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.81% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MYMX Stock
  4. Company Mymetics Corporation